Jan 20 (Reuters) - Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have ...
Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.
Stocktwits on MSN
Novo Nordisk inks deal with Canada’s Aspect Biosystems to find more diabetes meds besides Ozempic
Novo and Aspect have been collaborating since 2023 to develop cellular medicines. ・Under the deal, Aspect has acquired rights ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced that it has received a $72.75 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback